TD Cowen analyst Kyle Boucher raised the firm’s price target on Bio-Techne (TECH) to $70 from $65 and keeps a Buy rating on the shares. The firm noted consensus estimates have moved lower since F4Q earnings, and while they lowered their estimates for 1H2026 given difficult year-over-year comparisons, they maintain their positive view on shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TECH:
- Bio-Techne and Oxford Nanopore Technologies extend genetics collaboration
- Bio-Techne upgraded to Outperform from Sector Perform at RBC Capital
- Bio-Techne upgraded to Outperform at RBC on forecast multiple expansion
- CoreWeave upgraded, Instacart downgraded: Wall Street’s top analyst calls
- Bio-Techne upgraded to Buy from Neutral at Citi